|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q3 FY2018
As of Sep 30, 2018
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Marketable debt securities | ||||||||||||||||||||
| Accounts receivable, net | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Income tax receivable | ||||||||||||||||||||
| Inventory, current | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use-assets | ||||||||||||||||||||
| Inventory, noncurrent | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders' equity (deficit) | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued direct research liabilities | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Liability related to sale of future royalties, current | ||||||||||||||||||||
| Operating lease liabilities, current | ||||||||||||||||||||
| Payable to collaborators | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Other long-term liabilities | ||||||||||||||||||||
| Term loan, net of debt issuance costs | ||||||||||||||||||||
| Opearting lease liabilities, noncurrent | ||||||||||||||||||||
| Term Loan, net of debt issuance cost | ||||||||||||||||||||
| Liability related to sale of future royalties, non-current | ||||||||||||||||||||
| Liability related to sale of future royalties, net | ||||||||||||||||||||
| Payable to collaborators, net of current portion | ||||||||||||||||||||
| Deferred revenue, net of current portion | ||||||||||||||||||||
| Total noncurrent liabilities | ||||||||||||||||||||
| Stockholders' equity (deficit): | ||||||||||||||||||||
| Common stock value | ||||||||||||||||||||
| Common Stock A | ||||||||||||||||||||
| Common Stock B | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Common Stock A | ||||||||||||||||||||
| Common Stock B | ||||||||||||||||||||
| Total stockholders' equity (deficit) | ||||||||||||||||||||
| Total liabilities and stockholders' equity (deficit) | ||||||||||||||||||||
Loading...
